Citations

Clear

119 citation(s) found for "Sheehan, J".

Stereotactic radiosurgery in the management of non–small cell lung cancer brain metastases: a prospective study using the NeuroPoint Alliance Stereotactic Radiosurgery Registry
Michalopoulos, Giorgos D. , Grills, Inga S., Warnick, Ronald E. , McInerney, James , Attia, Albert, Timmerman, Robert , Chang, Eric L. , D’Ambrosio, Anthony, Cobb, William S., Spalding, Aaron C., Walter, Kevin A. , Jensen, Randy L. , Bydon, Mohamad , Asher, Anthony L. , Sheehan, Jason P. , Katsos, Konstantinos, Michalopoulos, Giorgos , Katsos, Konstantinos, Andrews, David William , Cobb, William S., Pouratian, Nader

Mayo Clinic

Journal of Neurosurgery | November 11, 2023 | Volume: 140 | Issue: 5 | Pages: 1223-1232

10.3171/2023.8.jns23308 | PMID 37948684 Get It

OBJECTIVE The literature on non–small cell lung cancer (NSCLC) brain metastases (BMs) managed using stereotactic radiosurgery (SRS) relies mainly on single-institution studies or randomized controlled trials (RCTs). There is a literature gap on clinical and radiological outcomes of SRS for NSCLC metastases in real-world practice. The objective of this study was to benchmark mortality and progression outcomes in patients undergoing SRS for NSCLC BMs and identify risk factors for these outcomes using a national quality registry. METHODS The SRS Registry of the NeuroPoint Alliance was used for this study. This registry included patients from 16 enrolling sites who underwent SRS from 2017 to 2022. Data are prospectively collected without a prespecified research purpose. The main outcomes of this analysis were overall survival (OS), out-of-field recurrence, local progression, and intracranial progression. All time-to-event investigations included Kaplan-Meier analyses and multivariable Cox regressions. RESULTS Two hundred sixty-four patients were identified, with a mean age of 66.7 years and a female proportion of 48.5%. Most patients (84.5%) had a Karnofsky Performance Status (KPS) score of 80–100, and the mean baseline EQ-5D score was 0.539 quality-adjusted life years. A single lesion was present in 53.4% of the patients, and 29.1% of patients had 3 or more lesions. The median OS was 28.1 months, and independent predictors of mortality included no control of primary tumor (hazard ratio [HR] 2.1), KPS of 80 (HR 2.4) or lower (HR 2.4), coronary artery disease (HR 2.8), and 5 or more lesions present at the time of SRS treatment (HR 2.3). The median out-of-field progression-free survival (PFS) was 24.8 months, and the median local PFS was unreached. Intralesional hemorrhage was an independent risk factor of local progression, with an HR of 6.0. The median intracranial PFS was 14.0 months and was predicted by the number of lesions at the time of SRS (3–4 lesions, HR 2.2; 5–14 lesions, HR 2.5). CONCLUSIONS In this real-world prospective study, the authors used a national quality registry and found favorable OS in patients with NSCLC BMs undergoing SRS compared with results from previously published RCTs. The intracranial PFS was mainly driven by the emergence of new lesions rather than local progression. A greater number of lesions at baseline was associated with out-of-field progression, while intralesional hemorrhage at baseline was associated with local progression.
SAT257 Efficacy Of Oral Cinacalcet In Non-PTH Non-Malignant Hypercalcemia From Excess 1,25 Dihydroxyvitamin D
Mohan, Sneha , Sheehan, Michael T. , Wermers, Robert A. , Tebben, Peter J.

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.553 Get It

Abstract Disclosure: S. Mohan: None. M.T. Sheehan: None. P.J. Tebben: None. R.A. Wermers: None. Introduction: Elevated 1,25-dihydroxyvitamin D (1,25(OH)2D) is a rare cause of non-parathyroid hormone (PTH) mediated hypercalcemia. An increase in the activating enzyme 1-alpha hydroxylase is seen in granulomatous diseases and lymphoma, while mutations in the CYP24A1 gene leads to reduced catabolism of 1,25(OH)2D. Cinacalcet has been shown to successfully treat 1,25(OH)2D-mediated hypercalcemia of malignancy. Extrapolating this, we report 3 patients with non-malignant 1,25(OH)2D-mediated hypercalcemia treated with cinacalcet. Case Series: The patients (2 male and 1 female) were 55-71 years old. At presentation to our clinic, all had hypercalcemia with serum calcium concentrations between 10.6-11.5 mg/dL (normal, 8.8-10.2 mg/dL). PTH ranged between 16-35 pg/ml (normal 15-65 pg/ml), PTH-related peptide was normal in all patients, 25-hydroxyvitamin D was 32-51 ng/ml, and 1,25(OH)2D was inappropriately normal between 31-77 pg/ml (normal 18-78 pg/mL) in the setting of hypercalcemia and chronic kidney disease in 2 patients with estimated glomerular filtration rates 35-42 ml/min. Other causes of hypercalcemia including sarcoidosis, tuberculosis and malignancy were ruled out. The female patient had hypercalciuria (288 mg/24 hours) without nephrolithiasis and both male patients had severe hypercalciuria (400-660 mg/24 hours) with recurrent nephrolithiasis. One male patient had biallelic variants in the CYP24A1 gene, while the other male patient was suspected to have similar mutations, but not identified on genetic testing. The female patient with a PTH of 35 pg/mL on our initial measurement had documented 1,25(OH)2D level of 82 pg/mL with PTH <20 pg/mL while previously hypercalcemic. Upon cinacalcet initiation all patients demonstrated normalization of calcium levels (8.6-9.5 mg/dl) with doses between 30-90 mg daily. The patient with CYP24A1 gene mutations experienced symptomatic hypocalcemia with calcium of 8.1 mg/dL requiring dose reduction and eventual discontinuation of cinacalcet due to limited clinical benefit. There were no consistent changes in 24-hour urine calcium or fractional excretion of calcium. Levels of 1,25(OH)2D increased and PTH decreased on cinacalcet while serum calcium levels were maintained within normal range, including 2 subjects with continued normocalcemia after 2 years of therapy. Conclusion: Cinacalcet may be a therapeutic option in non-malignant 1,25(OH)2D-mediated hypercalcemia. Further evaluation is needed to confirm efficacy, understand risks and benefits, and elucidate potential mechanisms of action. Mild decrease in PTH may lead to reduced skeletal calcium efflux while the maintenance of normocalcemia despite rising 1,25(OH)2D, which was also seen in our reported patients with malignant 1,25(OH)2D-mediated hypercalcemia, suggests cinacalcet may decrease intestinal calcium absorption. Presentation: Saturday, June 17, 2023
Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE)
Rusthoven, Chad G. , Staley, Alyse , Yomo, Shoji , Bernhardt, Denise , Wandrey, Narine , Shafie, Rami A. El , Kraemer, Anna, Padilla, Oscar , Chiang, Veronica , Faramand, Andrew , Wegner, Rodney E. , Hattangadi‐Gluth, Jona A. , Lévy, Antonin , Bernstein, Kenneth , Mathieu, David , Cagney, Daniel , Grills, Inga S., Lee, Cheng-chia, Sheehan, Jason , Kluwe, Christien, Patel, Samir H. , Halasz, Lia M. , Andratschke, Nicolaus , Deibert, Christopher P., Cifarelli, Christopher P. , Debus, Jürgen, Aoyagi, Kyoko , Brown, Paul D. , Alami, Vida, Niranjan, Ajay , Lunsford, L. Dade , Camidge, D Ross, Kavanagh, Brian D. , Serizawa, Toru , Yamamoto, Masaaki, Bernhardt, Denise , Zacharia, Brad E , Andratschke, Nicolaus , Trifiletti, Daniel M , Mathieu, David , Robin, Tyler P. , Gao, Dexiang , Palmer, Joshua D. , Zacharia, Brad E. , Chan, Michael David , Braunstein, Steve , Verma, Vivek, Trifiletti, Daniel M. , Combs, Stephanie Elisabeth , Sato, Yasunori , Higuchi, Yoshinori , Kondziolka, Douglas

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 4, 2023 | Volume: 115 | Issue: 8 | Pages: 926-936

10.1093/jnci/djad073 | PMID 37142267 Get It

Abstract Introduction Historical reservations regarding stereotactic radiosurgery (SRS) for small-cell lung cancer (SCLC) brain metastases include concerns for short-interval and diffuse central nervous system (CNS) progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small cell lung cancer (NSCLC) where SRS is well established. Methods Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000 to 2022 were retrospectively collected (n = 892 SCLC, n = 4785 NSCLC). Data from the prospective Japanese Leksell Gamma Knife Society (JLGK0901) clinical trial of first-line SRS were analyzed as a comparison cohort (n = 98 SCLC, n = 814 NSCLC). Overall survival (OS) and CNS progression were analyzed using Cox proportional hazard and Fine-Gray models, respectively, with multivariable adjustment for cofactors including age, sex, performance status, year, extracranial disease status, and brain metastasis number and volume. Mutation-stratified analyses were performed in propensity score–matched retrospective cohorts of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive NSCLC, mutation-negative NSCLC, and SCLC. Results OS was superior for patients with NSCLC compared to SCLC in the retrospective dataset (median OS = 10.5 vs 8.6 months; P < .001) and in the JLGK0901 dataset. Hazard estimates for first CNS progression favoring NSCLC were similar in both datasets but reached statistical significance in the retrospective dataset only (multivariable hazard ratio = 0.82, 95% confidence interval = 0.73 to 0.92, P = .001). In the propensity score–matched cohorts, there were continued OS advantages for NSCLC patients (median OS = 23.7 [EGFR and ALK positive NSCLC] vs 13.6 [mutation-negative NSCLC] vs 10.4 months [SCLC], pairwise P values < 0.001), but no statistically significant differences in CNS progression were observed in the matched cohorts. Neurological mortality and number of lesions at CNS progression were similar for NSCLC and SCLC patients. Leptomeningeal progression was increased in patients with NSCLC compared to SCLC in the retrospective dataset only (multivariable hazard ratio = 1.61, 95% confidence interval = 1.14 to 2.26, P = .007). Conclusions After SRS, SCLC histology was associated with shorter OS compared to NSCLC. CNS progression occurred earlier in SCLC patients overall but was similar in patients matched on baseline factors. SCLC was not associated with increased neurological mortality, number of lesions at CNS progression, or leptomeningeal progression compared to NSCLC. These findings may better inform clinical expectations and individualized decision making regarding SRS for SCLC patients.
Local Control and Survival Outcomes After Stereotactic Radiosurgery for Brain Metastases From Gastrointestinal Primaries: An International Multicenter Analysis
Singh, Raj , Bowden, Greg , Mathieu, David , Perlow, Haley K. , Elhamdani, Shahed, Shepard, Matthew J., Liang, Yun , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , Emad, Reem M. , Elazzazi, Ahmed Hesham, Warnick, Ronald E. , Gozal, Yair M., Daly, Megan, McShane, Brendan, Addis-Jackson, Marcel, Karthikeyan, Gokul, Franzini, Andrea , Wei, Zhishuo , Legarreta, Aimé Parra , Hess, Judith, Templeton, Kelsey, Pikis, Stylianos , Mantziaris, Georgios , Peker, Selçuk , Samancı, Yavuz , Chiang, Veronica , Niranjan, Ajay , Kersh, Charles R. , Lee, Cheng‐Chia , Lunsford, L. Dade , Sheehan, Jason P. , Mathieu, David , Mantziaris, Georgios , Perlow, Haley K , Palmer, Joshua D. , Elhamdani, Shahed, Reda, Wael A. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Karthikeyan, Gokul, Smith, Sian K. , Picozzi, Piero , Kaisman‐Elbaz, Tehila , Yang, Huai‐Che , Šimonová, Gabriela , Liščák, Roman , Trifiletti, Daniel M.

Mayo Clinic

Neurosurgery | March 21, 2023 | Volume: 93 | Issue: 3 | Pages: 592-598

10.1227/neu.0000000000002456 | PMID 36942965 Get It

BACKGROUND: There are limited data regarding outcomes for patients with gastrointestinal (GI) primaries and brain metastases treated with stereotactic radiosurgery (SRS). OBJECTIVE: To examine clinical outcomes after SRS for patients with brain metastases from GI primaries and evaluate potential prognostic factors. METHODS: The International Radiosurgery Research Foundation centers were queried for patients with brain metastases from GI primaries managed with SRS. Primary outcomes were local control (LC) and overall survival (OS). Kaplan-Meier analysis was used for univariate analysis (UVA) of prognostic factors. Factors significant on UVA were evaluated with a Cox multivariate analysis proportional hazards model. Logistic regressions were used to examine correlations with RN. RESULTS: We identified 263 eligible patients with 543 brain metastases. Common primary sites were rectal (31.2%), colon (31.2%), and esophagus (25.5%) with a median age of 61.6 years (range: 37-91.4 years) and a median Karnofsky performance status (KPS) of 90% (range: 40%-100%). One-year and 2-year LC rates were 83.5% (95% CI: 78.9%-87.1%) and 73.0% (95% CI: 66.4%-78.5%), respectively. On UVA, age >65 years ( P = .001), dose <20 Gy ( P = .006) for single-fraction plans, KPS <90% ( P < .001), and planning target volume ≥2cc ( P = .007) were associated with inferior LC. All factors other than dose were significant on multivariate analysis ( P ≤ .002). One-year and 2-year OS rates were 68.0% (95% CI: 61.5%-73.6%) and 31.2% (95% CI: 24.6%-37.9%), respectively. Age > 65 years ( P = .006), KPS <90% ( P = .005), and extracranial metastases ( P = .05) were associated with inferior OS. CONCLUSION: SRS resulted in comparable LC with common primaries. Age and KPS were associated with both LC and OS with planning target volume and extracranial metastases correlating with LC and OS, respectively. These factors should be considered in GI cancer patient selection for SRS.
Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study
Lee, Jessica , Currow, David C. , Phillips, Jane , McLachlan, Andrew J. , Ritchie, Megan, Fazekas, Belinda, Aggarwal, Rajesh , Seah, Davinia , Chye, Richard , Noble, Beverly, Aggarwal, Ghauri, George, Rachel, Kow, Marian, Ayoub, Chadi , Linton, Anthony , Sanderson, Christine , Mittal, Dipti, Rao, Angela , Prael, Grace , Urban, Katalin, Vandersman, Priyanka , Agar, Meera , McCaffrey, Nikki , Lovell, Melanie R , Brown, Linda , Sheehan, Caitlin

Mayo Clinic

BMJ Open | February 21, 2023 | Volume: 13 | Issue: 2 | Pages: e066125

10.1136/bmjopen-2022-066125 | PMID 36810169 Get It

Introduction Many patients experience unrelieved neuropathic cancer-related pain. Most current analgesic therapies have psychoactive side effects, lack efficacy data for this indication and have potential medication-related harms. The local anaesthetic lidocaine (lignocaine) has the potential to help manage neuropathic cancer-related pain when administered as an extended, continuous subcutaneous infusion. Data support lidocaine as a promising, safe agent in this setting, warranting further evaluation in robust, randomised controlled trials. This protocol describes the design of a pilot study to evaluate this intervention and explains the pharmacokinetic, efficacy and adverse effects evidence informing the design. Methods and analysis A mixed-methods pilot study will determine the feasibility of an international first, definitive phase III trial to evaluate the efficacy and safety of an extended continuous subcutaneous infusion of lidocaine for neuropathic cancer-related pain. This study will comprise: a phase II double-blind randomised controlled parallel-group pilot of subcutaneous infusion of lidocaine hydrochloride 10% w/v (3000 mg/30 mL) or placebo (sodium chloride 0.9%) over 72 hours for neuropathic cancer-related pain, a pharmacokinetic substudy and a qualitative substudy of patients’ and carers’ experiences. The pilot study will provide important safety data and help inform the methodology of a definitive trial, including testing proposed recruitment strategy, randomisation, outcome measures and patients’ acceptability of the methodology, as well as providing a signal of whether this area should be further investigated. Ethics and dissemination Participant safety is paramount and standardised assessments for adverse effects are built into the trial protocol. Findings will be published in a peer-reviewed journal and presented at conferences. This study will be considered suitable to progress to a phase III study if there is a completion rate where the CI includes 80% and excludes 60%. The protocol and Patient Information and Consent Form have been approved by Sydney Local Health District (Concord) Human Research Ethics Committee 2019/ETH07984 and University of Technology Sydney ETH17-1820. Trial registration number ANZCTR ACTRN12617000747325.
Fall Prevention Training for Service Members With an Amputation or Limb Salvage Following Lower Extremity Trauma
Miller, Emily J. , Deml, Christine M, Sheehan, Riley C. , Grabiner, Mark D., Wyatt, Marilynn, Zai, Claire Z. , Kingsbury, Trevor , Tullos, Meghan L. , Acasio, Julian C. , Mahon, Caitlin E. , Kaufman, Kenton R. , Hendershot, Brad D. , Dearth, Christopher L.

Mayo Clinic

Military Medicine | February 16, 2023 | Volume: 189 | Issue: 5-6 | Pages: 980-987

10.1093/milmed/usad005 | PMID 36794799 Get It

ABSTRACT Introduction Recent military conflicts have resulted in a significant number of lower extremity injuries to U.S. service members that result in amputation or limb preservation (LP) procedures. Service members receiving these procedures report a high prevalence and deleterious consequences of falls. Very little research exists to improve balance and reduce falls, especially among young active populations such as service members with LP or limb loss. To address this research gap, we evaluated the success of a fall prevention training program for service members with lower extremity trauma by (1) measuring fall rates, (2) quantifying improvements in trunk control, and (3) determining skill retention at 3 and 6 months after training. Materials and Methods Forty-five participants (40 males, mean [±SD] age, 34 ± 8 years) with lower extremity trauma (20 with unilateral transtibial amputation, 6 with unilateral transfemoral amputation, 5 with bilateral transtibial amputation, and 14 with unilateral LP procedures) were enrolled. A microprocessor-controlled treadmill was used to produce task-specific postural perturbations which simulated a trip. The training was conducted over a 2-week period and consisted of six 30-minute sessions. The task difficulty was increased as the participant’s ability progressed. The effectiveness of the training program was assessed by collecting data before training (baseline; repeated twice), immediately after training (0 month), and at 3 and 6 months post-training. Training effectiveness was quantified by participant-reported falls in the free-living environment before and after training. Perturbation-induced recovery step trunk flexion angle and velocity was also collected. Results Participants reported reduced falls and improved balance confidence in the free-living environment following the training. Repeated testing before training revealed that there were no pre-training differences in trunk control. The training program improved trunk control following training, and these skills were retained at 3 and 6 months after training. Conclusion This study showed that task-specific fall prevention training reduced falls across a cohort of service members with diverse types of amputations and LP procedures following lower extremity trauma. Importantly, the clinical outcome of this effort (i.e., reduced falls and improved balance confidence) can lead to increased participation in occupational, recreational, and social activities and thus improved quality of life.
Effects of Neuroanatomic Structural Distances on Pituitary Function After Stereotactic Radiosurgery: A Multicenter Study
Ironside, Natasha , Xu, Zhiyuan , Schlesinger, David, Vance, Mary Lee, Hong, Gregory K. , Jane, John A. , Patel, Samir , Bindal, Shray K., Niranjan, Ajay , Lunsford, L. Dade , Chytka, Thomas, Berger, Assaf , Bernstein, Kenneth , Hernández, Wenceslao, Lazo, Erwin , Peker, Selçuk , Samancı, Yavuz , Mau, Christine, Wegner, Rodney E. , Shepard, Matthew J., Mathieu, David , Maillet, Michel, Sheehan, Jason P. , Mathieu, David , Chen, Ching‐Jen , Bindal, Shray Kumar, Liščák, Roman , Ježková, Jana , Saifi, Omran , Trifiletti, Daniel M. , Alzate, Juan, Kondziolka, Douglas , Speckter, Herwin , Zacharia, Brad E.

Mayo Clinic

Neurosurgery | January 26, 2023 | Volume: 92 | Issue: 5 | Pages: 1035-1042

10.1227/neu.0000000000002347 | PMID 36700741 Get It

BACKGROUND: Delayed hypopituitarism is the most common complication after stereotactic radiosurgery (SRS) for pituitary adenomas. OBJECTIVE: To investigate the relationship between neuroanatomic structure distances from the radiation target and anterior pituitary function preservation after SRS through multicenter study. METHODS: We retrospectively reviewed the International Radiosurgery Research Foundation database from January 2002 to December 2021 for adult patients undergoing SRS for pituitary adenomas with >6 months of follow-up. Distances between centers or edges of hypothalamic-pituitary axis structures and SRS target volumes were measured using MRI. The primary outcome was anterior pituitary function preservation. Predictors were analyzed using multivariable logistic regression and area under the receiver operating curve (AUROC) curve analyses. RESULTS: Four hundred eighty-seven patients were categorized by preservation (n = 384) and no preservation (n = 103) of anterior pituitary function. The mean margin dose was 19.1(6.2) Gy. Larger distance from the center of the stalk to the tumor margin isodose was a positive predictor (adjusted odds ratio [aOR] = 1.162 [1.046-1.291], P = .005), while pre-SRS hypopituitarism (aOR = 0.646 [0.405-1.031], P = .067) and larger treatment volume (aOR = 0.965 [0.929-1.002], P = .061) were near negative predictors of the primary outcome. An interaction between the treatment volume and center stalk to margin isodose distance was found (aOR = 0.980 [0.961-0.999], P = .045). Center stalk to margin isodose distance had an AUROC of 0.620 (0.557-0.693), at 3.95-mm distance. For patients with treatment volumes of <2.34 mL, center stalk to margin isodose distance had an AUROC of 0.719 (0.614-0.823), at 2.95-mm distance. CONCLUSION: Achieving a distance between the center of the pituitary stalk and the tumor margin isodose ≥3.95 mm predicted anterior pituitary function preservation. For smaller treatment volumes <2.34 mL, the optimal distance was ≥2.95 mm. This may be modifiable during trans-sphenoidal resection to preserve pituitary function.
Stereotactic Radiosurgery for Intraventricular Metastases: A Multicenter Study
Mantziaris, Georgios , Pikis, Stylianos , Xu, Zhiyuan , Mullen, Reed, Bernstein, Kenneth , Wei, Zhishuo , Niranjan, Ajay , Lunsford, L. Dade , May, Jaromír , Lee, Cheng-chia, Coupé, François-Louis, Mathieu, David , Sheehan, Kimball , Sheehan, Darrah, Perlow, Haley K. , Peker, Selçuk , Samancı, Yavuz , Peterson, Jennifer , Shepard, Matthew J., Elhamdani, Shahed, Wegner, Rodney E. , Hernández, Wenceslao, Warnick, Ronald E. , Sheehan, Jason P. , Mathieu, David , Mantziaris, Georgios , Perlow, Haley K , Alzate, Juan Diego , Kondziolka, Douglas , Liščák, Roman , Yang, Huai‐Che , Palmer, Joshua D. , Trifiletti, Daniel M. , Elhamdani, Shahed, Speckter, Herwin

Mayo Clinic

Neurosurgery | December 13, 2022 | Volume: 92 | Issue: 3 | Pages: 565-573

10.1227/neu.0000000000002248 | PMID 36512817 Get It

BACKGROUND: Intraventricular metastases (IVMs) are uncommon, and their optimal management remains debatable. OBJECTIVE: To define the safety and efficacy of stereotactic radiosurgery (SRS) in the treatment of IVMs. METHODS: This retrospective, multicenter study included patients managed with SRS for IVMs. SRS-induced adverse events, local tumor or intracranial progression, and the frequency of new-onset hydrocephalus or leptomeningeal spread were documented. Analyses of variables related to patient neuroimaging or clinical outcomes were also performed. RESULTS: The cohort included 160 patients from 11 centers who underwent SRS for treatment of 1045 intracranial metastases, of which 196 were IVMs. The median survival from SRS was 10 months. Of the 154 patients and 190 IVMs with imaging follow-up, 94 patients (61%) experienced distant intracranial disease progression and 16 IVMs (8.4%) progressed locally. The 12- and 24-month local IVM control rates were 91.4% and 86.1%, respectively. Sixteen (10%) and 27 (17.5%) patients developed hydrocephalus and leptomeningeal dissemination post-SRS, respectively. Adverse radiation effects were documented in 24 patients (15%). Eleven patients (6.9%) died because of intracranial disease progression. CONCLUSION: SRS is an effective treatment option for IVMs, with a local IVM control rate comparable with SRS for parenchymal brain metastases. Leptomeningeal spread and hydrocephalus in patients with IVM occur in a minority of patients, but these patients warrant careful follow-up to detect these changes.
Facial Nerve Schwannoma Treatment with Stereotactic Radiosurgery (SRS) versus Resection followed by SRS: Outcomes and a Management Protocol
Dayawansa, Sam , Mantziaris, Georgios , Mehta, Gautam U. , Leković, Gregory P. , Mathieu, David , Reda, Wael A. , Lee, Cheng-chia, Barnet, Gene, Lunsford, L. Dade , Sheehan, Jason P. , Mehta, Gautam U , Mathieu, David , Trifiletti, Daniel M , Mantziaris, Georgios , Dumot, Chloé , Kondziolka, Douglas , Reda, Wael A. , Liščák, Roman , Kaufmann, Anthony M. , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | December 1, 2022 | Volume: 85 | Issue: 01 | Pages: 075-080

10.1055/a-1990-2861 | PMID 38274481 Get It

Abstract Background Stereotactic radiosurgery (SRS) and resection are treatment options for patients with facial nerve schwannomas without mass effect. Objective This article evaluates outcomes of patients treated with SRS versus resection + SRS. Method We retrospectively compared 43 patients treated with SRS to 12 patients treated with resection + SRS. The primary study outcome was unfavorable combined endpoint, defined as worsening or new clinical symptoms, and/or tumor radiological progression. SRS (38.81 ± 5.3) and resection + SRS (67.14 ± 11.8) groups had similar clinical follow-ups. Results At the time of SRS, the tumor volumes of SRS (mean ± standard error; 1.83 ± 0.35 mL) and resection + SRS (2.51 ± 0.75 mL) groups were similar. SRS (12.15 ± 0.08 Gy) and resection + SRS (12.16 ± 0.14 Gy) groups received similar radiation doses. SRS group (42/43, 98%) had better local tumor control than the resection + SRS group (10/12, 83%, p = 0.04). Most of SRS (32/43, 74%) and resection + SRS (10/12, 83%) group patients reached a favorable combined endpoint following SRS (p = 0.52). Considering surgical associated side effects, only 2/10 patients of the resection + SRS group reached a favorable endpoint (p < 0.001).Patients of SRS group, who are > 34 years old (p = 0.02), have larger tumors (> 4 mL, 0.04), internal auditory canal (IAC) segment tumor involvement (p = 0.01) were more likely to reach an unfavorable endpoint. Resection + SRS group patients did not show such a difference. Conclusion While resection is still needed for larger tumors, SRS offers better clinical and radiological outcomes compared to resection followed by SRS for facial schwannomas. Younger age, smaller tumors, and non-IAC situated tumors are factors that portend a favorable outcome.
Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer
Niranjan, Ajay , Hess, Judith, Antonios, Joseph , Zhang, Michael Y. , Ross, Richard B. , Pikis, Stylianos , Deibert, Christopher P., Lee, Cheng-chia, Langlois, Anne-Marie, Mathieu, David , Peker, Selçuk , Samancı, Yavuz , Rusthoven, Chad G. , Chiang, Veronica , Wei, Zhishuo , Lunsford, L. Dade , Sheehan, Jason P. , Mathieu, David , Kowalchuk, Roman O. , Braunstein, Steve , Yang, Huai‐Che , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | November 25, 2022 | Volume: 138 | Issue: 6 | Pages: 1608-1614

10.3171/2022.10.jns221900 | PMID 36433878 Get It

OBJECTIVE Stereotactic radiosurgery (SRS) is an effective treatment for intracranial metastatic disease, but its role in triple-negative breast cancer requires further study. Herein, the authors report overall survival (OS) and local tumor control in a multiinstitutional cohort with triple-negative breast cancer metastases treated with SRS. METHODS Patients treated from 2010 to 2019 at 9 institutions were included in this retrospective study if they had biopsy-proven triple-negative breast cancer with intracranial metastatic lesions treated with SRS. Patients were excluded if they had undergone prior SRS, whole-brain radiation therapy, or resection of the metastatic lesions. A retrospective chart review was conducted to determine OS, local control, and treatment efficacy. RESULTS Sixty-eight patients with 315 treated lesions were assessed. Patients had a median Karnofsky Performance Status of 80 (IQR 70–90) and age of 57 years (IQR 48–67 years). Most treated patients had 5 or fewer intracranial lesions, with 34% of patients having a single lesion. Treated lesions were small, having a median volume owf 0.11 cm3 (IQR 0.03–0.60 cm3). Patients were treated with a median margin dose of 18 Gy (IQR 18–20 Gy) to the median 71% isodose line (IQR 50%–84%). Overall, patients had a 1-year OS of 43% and 2-year OS of 20%. Most patients (88%) were followed until death, by which time local tumor progression had occurred in only 7% of cases. Furthermore, 76% of the lesions demonstrated regression. Tumor volume was correlated with local tumor progression (p = 0.012). SRS was very well tolerated, and only 3 patients (5%) developed symptomatic radiation necrosis. CONCLUSIONS SRS is a safe and efficacious treatment for well-selected patients with triple-negative breast cancer, especially for those with a favorable performance status and small- to moderate-volume metastatic lesions.